192 related articles for article (PubMed ID: 29313296)
1. The biological effects of the hypolipidaemic drug probucol microcapsules fed daily for 4 weeks, to an insulin-resistant mouse model: potential hypoglycaemic and anti-inflammatory effects.
Mooranian A; Negrulj R; Takechi R; Mamo J; Al-Sallami H; Al-Salami H
Drug Deliv Transl Res; 2018 Jun; 8(3):543-551. PubMed ID: 29313296
[TBL] [Abstract][Full Text] [Related]
2. Bile acid-polymer-probucol microparticles: protective effect on pancreatic β-cells and decrease in type 1 diabetes development in a murine model.
Mooranian A; Zamani N; Luna G; Al-Sallami H; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Kovacevic B; Al-Salami H
Pharm Dev Technol; 2019 Dec; 24(10):1272-1277. PubMed ID: 31557068
[TBL] [Abstract][Full Text] [Related]
3. The effect of a tertiary bile acid, taurocholic acid, on the morphology and physical characteristics of microencapsulated probucol: potential applications in diabetes: a characterization study.
Mooranian A; Negrulj R; Arfuso F; Al-Salami H
Drug Deliv Transl Res; 2015 Oct; 5(5):511-22. PubMed ID: 26242686
[TBL] [Abstract][Full Text] [Related]
4. Bile acid bio-nanoencapsulation improved drug targeted-delivery and pharmacological effects via cellular flux: 6-months diabetes preclinical study.
Mooranian A; Raj Wagle S; Kovacevic B; Takechi R; Mamo J; Lam V; Watts GF; Mikov M; Golocorbin-Kon S; Stojanovic G; Al-Sallami H; Al-Salami H
Sci Rep; 2020 Jan; 10(1):106. PubMed ID: 31919411
[TBL] [Abstract][Full Text] [Related]
5. Multicompartmental, multilayered probucol microcapsules for diabetes mellitus: Formulation characterization and effects on production of insulin and inflammation in a pancreatic β-cell line.
Mooranian A; Negrulj R; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2016 Nov; 44(7):1642-53. PubMed ID: 26377035
[TBL] [Abstract][Full Text] [Related]
6. Microencapsulation as a novel delivery method for the potential antidiabetic drug, Probucol.
Mooranian A; Negrulj R; Chen-Tan N; Al-Sallami HS; Fang Z; Mukkur TK; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Matthews V; Arfuso F; Al-Salami H
Drug Des Devel Ther; 2014; 8():1221-30. PubMed ID: 25246766
[TBL] [Abstract][Full Text] [Related]
7. Swelling, mechanical strength, and release properties of probucol microcapsules with and without a bile acid, and their potential oral delivery in diabetes.
Negrulj R; Mooranian A; Chen-Tan N; Al-Sallami HS; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2016 Aug; 44(5):1290-7. PubMed ID: 25811999
[TBL] [Abstract][Full Text] [Related]
8. Eudragit
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
Ther Deliv; 2018 Nov; 9(11):811-821. PubMed ID: 30444461
[TBL] [Abstract][Full Text] [Related]
9. An in vivo pharmacological study: Variation in tissue-accumulation for the drug probucol as the result of targeted microtechnology and matrix-acrylic acid optimization and stabilization techniques.
Mooranian A; Zamani N; Takechi R; Luna G; Mikov M; Goločorbin-Kon S; Elnashar M; Arfuso F; Al-Salami H
PLoS One; 2019; 14(4):e0214984. PubMed ID: 30947243
[TBL] [Abstract][Full Text] [Related]
10. Oral gavage of nano-encapsulated conjugated acrylic acid-bile acid formulation in type 1 diabetes altered pharmacological profile of bile acids, and improved glycaemia and suppressed inflammation.
Mooranian A; Zamani N; Ionescu CM; Takechi R; Luna G; Mikov M; Goločorbin-Kon S; Kovačević B; Al-Salami H
Pharmacol Rep; 2020 Apr; 72(2):368-378. PubMed ID: 32048259
[TBL] [Abstract][Full Text] [Related]
11. High-Loading Dose of Microencapsulated Gliclazide Formulation Exerted a Hypoglycaemic Effect on Type 1 Diabetic Rats and Incorporation of a Primary Deconjugated Bile Acid, Diminished the Hypoglycaemic Antidiabetic Effect.
Golocorbin-Kon S; Calasan J; Milijasevic B; Vukmirovic S; Lalic-Popovic M; Mikov M; Al-Salami H
Eur J Drug Metab Pharmacokinet; 2017 Dec; 42(6):1005-1011. PubMed ID: 28547295
[TBL] [Abstract][Full Text] [Related]
12. Pharmacological and Biological Study of Microencapsulated Probucol-Secondary Bile Acid in a Diseased Mouse Model.
Wagle SR; Kovacevic B; Ionescu CM; Walker D; Jones M; Carey L; Takechi R; Mikov M; Mooranian A; Al-Salami H
Pharmaceutics; 2021 Aug; 13(8):. PubMed ID: 34452184
[TBL] [Abstract][Full Text] [Related]
13. The incorporation of water-soluble gel matrix into bile acid-based microcapsules for the delivery of viable β-cells of the pancreas, in diabetes treatment: biocompatibility and functionality studies.
Mooranian A; Negrulj R; Al-Salami H
Drug Deliv Transl Res; 2016 Feb; 6(1):17-23. PubMed ID: 26671765
[TBL] [Abstract][Full Text] [Related]
14. Morphological, Stability, and Hypoglycemic Effects of New Gliclazide-Bile Acid Microcapsules for Type 1 Diabetes Treatment: the Microencapsulation of Anti-diabetics Using a Microcapsule-Stabilizing Bile Acid.
Mathavan S; Chen-Tan N; Arfuso F; Al-Salami H
AAPS PharmSciTech; 2018 Oct; 19(7):3009-3018. PubMed ID: 30062539
[TBL] [Abstract][Full Text] [Related]
15. An optimized probucol microencapsulated formulation integrating a secondary bile acid (deoxycholic acid) as a permeation enhancer.
Mooranian A; Negrulj R; Chen-Tan N; Watts GF; Arfuso F; Al-Salami H
Drug Des Devel Ther; 2014; 8():1673-83. PubMed ID: 25302020
[TBL] [Abstract][Full Text] [Related]
16. Probucol release from novel multicompartmental microcapsules for the oral targeted delivery in type 2 diabetes.
Mooranian A; Negrulj R; Al-Sallami HS; Fang Z; Mikov M; Golocorbin-Kon S; Fakhoury M; Watts GF; Matthews V; Arfuso F; Lambros A; Al-Salami H
AAPS PharmSciTech; 2015 Feb; 16(1):45-52. PubMed ID: 25168450
[TBL] [Abstract][Full Text] [Related]
17. Novel nano-encapsulation of probucol in microgels: scanning electron micrograph characterizations, buoyancy profiling, and antioxidant assay analyses.
Mooranian A; Zamani N; Mikov M; Goločorbin-Kon S; Stojanovic G; Arfuso F; Al-Salami H
Artif Cells Nanomed Biotechnol; 2018; 46(sup3):S741-S747. PubMed ID: 30260253
[TBL] [Abstract][Full Text] [Related]
18. Diabetes development increased concentrations of the conjugated bile acid, taurocholic acid in serum, while treatment with microencapsulated-taurocholic acid exerted no hypoglycaemic effects.
Mathavan S; Mikov M; Golocorbin-Kon S; Al-Salami H
Eur J Pharm Sci; 2017 Aug; 106():1-9. PubMed ID: 28529037
[TBL] [Abstract][Full Text] [Related]
19. Designing anti-diabetic β-cells microcapsules using polystyrenic sulfonate, polyallylamine, and a tertiary bile acid: Morphology, bioenergetics, and cytokine analysis.
Mooranian A; Negrulj R; Al-Salami H; Morahan G; Jamieson E
Biotechnol Prog; 2016 Mar; 32(2):501-9. PubMed ID: 26748789
[TBL] [Abstract][Full Text] [Related]
20. Innovative Microcapsules for Pancreatic β-Cells Harvested from Mature Double-Transgenic Mice: Cell Imaging, Viability, Induced Glucose-Stimulated Insulin Measurements and Proinflammatory Cytokines Analysis.
Mooranian A; Tackechi R; Jamieson E; Morahan G; Al-Salami H
Pharm Res; 2017 Jun; 34(6):1217-1223. PubMed ID: 28289997
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
